P12.49.b Quality of Life in Diffuse Lower Grade Glioma Patients Based on Adjuvant Treatment After Surgery: A Project From the Log-Glio Registry

BACKGROUND Quality of life (QoL) is a key consideration for patients with low-grade glioma (LGG), particularly due to the prolonged disease course and expanding treatment options. This study compared QoL outcomes between a “wait-and-scan” strategy and adjuvant treatment using data from the LoG-Glio Registry. MATERIAL AND METHODS QoL was assessed in 220 patients from the German prospective multicenter LoG-Glio Registry with IDH-mutant grade 2 and 3 diffuse gliomas. Patients completed the EORTC QLQ-C30 and BN-20 questionnaires over a 48-month postoperative period. Group comparisons were conducted using the Mann-Whitney U-test. A multivariate linear mixed model was used to identify QoL predictors, including age, gender, eloquent tumor location, pre-/postoperative deficits, preoperative ECOG status, diagnosis, type of surgery, residual tumor, and adjuvant treatment. RESULTS QoL data were available for all 220 patients. At 6 months post-surgery, patients who received adjuvant treatment had significantly lower overall QoL scores compared to the wait-and-scan group (69.4 vs. 77.0; p = 0.002). They also reported higher symptom burden (25.4 vs. 15.2; p = 0.003) and lower functioning scores (70.8 vs. 78.0; p = 0.04). Multivariate analysis confirmed a significant negative impact of adjuvant treatment at 6 months. By 12 months, these differences were no longer statistically significant. At 12 and 24 months, age was the only significant predictor of QoL decline (p = 0.009 and p = 0.012, respectively). CONCLUSION Adjuvant treatment in LGG is associated with lower QoL, increased symptoms, and reduced functioning in the first 6 months after surgery. These effects diminish over time, with QoL scores converging between treatment and observation groups by one year postoperatively.